Combining sEH inhibitors with traditional therapies may also be beneficial, as the dual use of a COX-2/sEH inhibitor decreased renal injury in T2DM Zucker rats via lower urine MCP-1 levels and macrophage infiltration, while administration of a dual acting PPARγ agonist-sEH inhibitor reduced renal interstitial fibrosis, and tubular and glomerular injury in obese diabetic ZSF1 rats [45,46]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.